2026-01-21 - Analysis Report
**Company Overview:**
Northrop Grumman is a leading American aerospace and defense technology company.

**Comparison of Return Rates:**
|  | Cumulative Return |
| --- | --- |
| Review Stock (NOC) | 57.79% |
| Comparison Stock (VOO) | 89.37% |
| Divergence (simply the difference in cumulative return on the last day of the data) | -31.58% |
| Relative Divergence (24.70%): indicates the current position when the minimum-maximum fluctuation range is set to 100. |

The review stock (NOC) has a lower cumulative return rate compared to the comparison stock (VOO).

**Alpha, Beta Analysis:**
|  | CAGR | MDD | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | -6.0% | 23.7% | -11.0% | 0.7 | 35.1B |
| 2017-2019 | 15.0% | 23.7% | -2.0% | 0.7 | 49.2B |
| 2018-2020 | -25.0% | 23.7% | -46.0% | 0.8 | 43.6B |
| 2019-2021 | 40.0% | 12.9% | -3.0% | 0.7 | 55.4B |
| 2020-2022 | 18.0% | 16.9% | 19.0% | 0.6 | 78.1B |
| 2021-2023 | 23.0% | 16.9% | 22.0% | 0.3 | 67.0B |
| 2022-2024 | -14.0% | 16.9% | -33.0% | 0.3 | 67.2B |
| 2023-2025 | -1.0% | 17.7% | -63.0% | 0.1 | 81.6B |

The review stock (NOC) has varying Alpha and Beta values over different time periods.

**Recent Stock Price Fluctuations:**
|  | Current Price | 5-day SMA | 20-day SMA | 60-day SMA |
| --- | --- | --- | --- | --- |
| Close | $657.30 | $651.49 | $604.82 | $580.37 |
| Last-Market | $657.30 |  |  |  |
| Divergence of SMA lines (simply): The 5-day and 20-day SMA lines are diverging upwards. |

The recent closing price is above the 5-day and 20-day SMA lines, indicating potential upward momentum.

**RSI, PPO Index Indicators and Other Analysis:**
|  | RSI | PPO | Hybrid Signal |
| --- | --- | --- | --- |
| Current | 70.91 | 1.15 | Buy |

The RSI is near the overbought zone, which may indicate potential downward momentum. The PPO is above 1, indicating potential upward momentum.

**Market Risk Indicator (MRI):**
|  | MRI |
| --- | --- |
| Current | 0.80 |

The MRI is at Medium Investment level.

**Delta_Previous_Relative_Divergence and Expected_Return:**
|  | Delta_Previous_Relative_Divergence | Expected_Return (%) |
| --- | --- | --- |
| Current | 11.40 (+) | -39.90% |

The recent relative divergence change is improving, but the expected return is negative.

**Recent Fluctuation Issue:**
The fluctuation issue may be due to the recent rebound from a sharp decline.

**Recent News & Significant Events:**
* [2026-01-20] Northrop Grumman (NOC) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
* [2026-01-08] Whatâ€™s The Risk For Northrop Grumman Stock As Trump Curbs Dividends And Executive Pay? - Forbes
* ... (other news)

These recent news articles may impact the stock's price and performance.

**Analyst Opinions:**
|  | Analyst Consensus |
| --- | --- |
| Key | Buy |
| Mean (1=StrongBuy~5=Sell) | 2.17 (~Buy) |
| Opinions | 21 |
| Target Price (avg/high/low) | 673.72 / 777.00 / 576.00 |

The analyst consensus is to Buy the stock, with a target price range of $673.72 to $777.00.

**Recent Earnings Analysis:**
|  | EPS | Revenue |
| --- | --- | --- |
| 2025-10-21 | 7.69 | $10.42B |
| 2025-07-22 | 8.17 | $10.35B |
| 2025-04-22 | 3.33 | $9.47B |
| 2024-10-24 | 7.02 | $10.00B |

The review stock (NOC) has varying earnings per share (EPS) and revenue over different quarters.

**Financial Information:**
**Revenue and Profitability:**
|  | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $10.42B | 21.37% |
| 2025-06-30 | $10.35B | 21.35% |
| 2025-03-31 | $9.47B | 16.69% |
| 2024-12-31 | $10.69B | 18.08% |
| 2024-09-30 | $10.00B | 21.07% |

The review stock (NOC) has varying revenue and profit margins over different quarters.

**Capital and Profitability:**
|  | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $15.99B | 6.88% |
| 2025-06-30 | $15.47B | 7.59% |
| 2025-03-31 | $14.98B | 3.21% |
| 2024-12-31 | $15.29B | 8.27% |
| 2024-09-30 | $14.75B | 6.96% |

The review stock (NOC) has varying equity and return on equity (ROE) over different quarters.

**Comprehensive Analysis (Summary of previous items):**

Overall, the review stock (NOC) has varying performance metrics over different time periods. The recent closing price is above the 5-day and 20-day SMA lines, indicating potential upward momentum. However, the RSI is near the overbought zone, which may indicate potential downward momentum. The expected return is negative, indicating potential downward momentum. The recent news articles may impact the stock's price and performance. The analyst consensus is to Buy the stock, with a target price range of $673.72 to $777.00.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.